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doi:10.1Objective: Pulmonary large cell neuroendocrine carcinoma is a rare high-grade malignant tumor. Because large
cell neuroendocrine carcinoma is rare, the optimal treatment, including perioperative chemotherapy, has not
been defined. We retrospectively analyzed the correlation among the effectiveness of perioperative chemother-
apy in treating large cell neuroendocrine carcinoma, pathologic stage, and immunoreactivity to neuroendocrine
markers.
Methods: A total of 63 patients with pulmonary large cell neuroendocrine carcinoma undergoing surgical re-
section from 2001 to 2009 were included. The resected tumors were immunohistochemically stained with the
3 neuroendocrine markers synaptophysin, chromogranin A, and neural cell adhesion molecule. We categorized
patients who were positive for all 3 markers as the triple-positive group and those who were negative for 1 or 2
markers as the non–triple-positive group.
Results: Perioperative chemotherapy resulted in better overall survival than surgery alone (P¼ .042). Multivar-
iate analysis of survival revealed that perioperative chemotherapy was a significant independent prognostic fac-
tor (hazard ratio, 0.323; 95% confidence interval, 0.112-0.934; P ¼ .0371). Among the patients who received
perioperative chemotherapy, the non–triple-positive group had a significantly greater 5-year survival rate than
the triple-positive group (P ¼ .0216). Moreover, among the non–triple-positive group, a significantly greater
5-year survival rate was observed for the patients who underwent surgery with chemotherapy than for those
who underwent surgery without chemotherapy (P ¼ .0081). In contrast, no difference was found in 5-year
survival between patients with chemotherapy and those without chemotherapy when the tumors were triple
positive.
Conclusions: Our results suggest that perioperative chemotherapy might benefit the survival of patients with
pulmonary large cell neuroendocrine carcinoma, in particular when the tumors are not immunoreactive to all
3 neuroendocrine markers. (J Thorac Cardiovasc Surg 2013;145:839-46)E
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SPulmonary large cell neuroendocrine carcinoma (LCNEC),
proposed as a separate tumor category by Travis and col-
leagues1 in 1991, is distinguished from typical carcinoid,
atypical carcinoid, and small-cell lung carcinoma (SCLC)
by its morphologic and biologic features. In 1999, the
World Health Organization classified LCNEC as a variant
of large cell carcinoma.2 Pulmonary LCNEC represents
about 2% to 3% of all lung malignancies and is associatede Departments of Thoracic Surgerya and Pathology,b Hyogo Cancer Center,
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The Journal of Thoracic and Cawith a worse prognosis than other non–SCLC (NSCLC),
even in the early stage.3-6 However, in a recent Japanese
study with a large sample size, Asamura and colleagues7
reported that no prognostic difference was found between
pulmonary LCNEC and SCLC.
Several small-scale retrospective studies have demon-
strated that perioperative chemotherapy could improve the
survival of patients with pulmonary LCNEC. Perioperative
chemotherapy is recommended even for patients with re-
sectable stage I LCNEC because of its aggressive course,
remarkably dismal prognosis, and high potential for metas-
tasis.8-11 However, owing to the rarity of this tumor, the
incidence, prognosis, and optimal treatment remain to be
determined.
In the present study, we retrospectively analyzed the effi-
cacy of perioperative chemotherapy in treating pulmonary
LCNEC. Furthermore, we examined the correlation be-
tween the sensitivity of LCNEC and perioperative chemo-
therapy and the immunohistochemical staining patterns ofrdiovascular Surgery c Volume 145, Number 3 839
Abbreviations and Acronyms
CPT-11 ¼ irinotecan
LCNEC ¼ large cell neuroendocrine carcinoma
NCAM ¼ neural cell adhesion molecule
NSCLC ¼ non–small-cell lung carcinoma
SCLC ¼ small-cell lung carcinoma
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Evolving Technology/Basic Science Tanaka et al
E
T
/B
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markers, synaptophysin, chromogranin A, and neural cell
adhesion molecule (NCAM). Although our experiences in
2 institutions do not allow us to reach a definite conclusion
owing to the small number of subjects, the present prelim-
inary study may be useful in generating a hypothesis to de-
termine the immunohistochemical biomarkers to predict
LCNEC’s response to perioperative chemotherapy in future
prospective multi-institutional trials.METHODS
We retrospectively examined the clinical data of 63 patients with pul-
monary LCNEC who underwent complete surgical resection from 2001
to 2009. All follow-up data were current as of December 31, 2011. All pa-
tients who underwent surgery in 2009 were included in the present study,
because more than 2 years have passed since their surgery. The median
follow-up period was 32.3 months (range, 2.8-95.3 months). The Hyogo
Cancer Center and Kobe University Hospital institutional review boards
approved the study, and each participant provided informed consent.
LCNEC was diagnosed using the following histopathologic criteria: (1)
neuroendocrine morphology such as an organoid, palisading, rosette-like,
or trabecular growth pattern; (2) high mitotic count (11/10 high-power
fields [HPF]); (3) tumor necrosis (often large zone); (4) large cell size
with low nuclear/cytoplasmic ratio, vesicular or fine chromatin, and/or
frequent nucleoli; and (5) positive immunostaining for 1 or more of the
neuroendocrine markers, synaptophysin, chromogranin A, and NCAM.2
Immunohistochemical stains were performed on 4-mm-thick, formalin-
fixed, paraffin-embedded sections. The deparaffinized sections underwent
CC1 buffer pretreatment (pH 8.5, ethylenediaminetetraacetic acid; Roche,
Mannheim, Germany) and were immunostained for the markers with the
streptavidin-biotin technique with an automated immunostainer (Benchi-
mark; Ventana, Tucson, Ariz) according to the manufacturer’s instructions.
Antibodies against chromogranin A (polyclonal, 1:500 dilution; Dako,
Glostrup, Denmark), synaptophysin (monoclonal, clone 27G12, 1:2 dilu-
tion; Nichirei, Tokyo, Japan), CD56 (NCAM; monoclonal, 1:100 dilution;
Novocastra, Newcastle, UK), and Ki-67 (monoclonal 1:100 dilution; Dako)
were used.
All samples were evaluated by an expert pathologist (C.O.) without
knowledge of the patient’s outcome. Plural sections, more than 10 sections
in most cases, were prepared in each case, and 1 representative specimen
involving tumor was selected for immunohistochemistry. The final results
were reported as negative (no positive cells) or positive (immunoreactive).
Proliferative activity was expressed as the MIB-1 index, which was calcu-
lated as the proportion of Ki-67–positive cells by counting 500 to 1000 can-
cer cells. The mitotic counts were performed using an Olympus BX53
microscope at a magnification of 3400, counting 3 sets of 10 HPF for
each tumor. The area with the greatest numbers of mitoses was counted.
In the present study, we included pure LCNEC and combined LCNEC,
in which at least 1 portion of neuroendocrine differentiation or morphology
in NSCLC was LCNEC. The medical records provided information on the840 The Journal of Thoracic and Cardiovascular Surgpatient age, gender, smoking status, pathologic stage, perioperative chemo-
therapy, and operative procedure. The determination of disease stage was
based on the TNM classification using the International Union Against
Cancer staging system.12
We classified patients into 2 groups to investigate the correlation
between the sensitivity of LCNEC to perioperative chemotherapy and
the results of immunohistochemical staining of neuroendocrine markers.
We categorized the patients who were positive for all 3 neuroendocrine
markers (ie, synaptophysin, chromogranin A, and NCAM) as the triple-
positive group and those who were negative for 1 or 2 of the markers
as the non–triple-positive group. Statistical analyses were performed us-
ing JMP, version 8, software (SAS Institute, Cary, NC). Student’s t-test
and the chi-square test were performed to assess the significance of the
differences in age, gender, smoking status, surgical procedure, and path-
ologic stage between the triple-positive and non–triple-positive groups.
Survival was calculated using the Kaplan-Meier method, and differences
in the distributions were evaluated using the log-rank test. The Cox pro-
portional hazards model was used to evaluate the association between the
prognostic factors and survival rate after pulmonary resection, with the
hazards ratio and 95% confidence intervals. Significance was set at
P< .05.RESULTS
The clinicopathologic characteristics of the 63 patients
with pulmonary LCNEC who underwent surgical resection
are listed in Table 1. The patient age ranged from 30 to 84
years (mean age, 67.0 years). Of the 63 patients, 54 (87%)
were men, and 58 (92%) were former or current smokers.
The surgical procedures included 55 lobectomies, 2 seg-
mentectomies, and 6 wedge resections with complete
resection (R0). Of the 55 lobectomies, 8 bronchoplastic pro-
cedures were performed and 6 extended resections were re-
quired because of tumor invasion into the adjacent tissue,
including muscle and rib (n ¼ 3), parietal pleura (n ¼ 1),
and vagal nerve (n ¼ 2). Of the 6 patients who underwent
extended resection, 5 were treated with chemotherapy. Be-
cause these patients had advanced-stage disease and the
number of the subjects was small, no correlation was found
between the extent of resection and the outcome.
The distribution of pathologic stage was stage IA in 19
patients (30%), stage IB in 16 (25%), stage IIA in 5
(8%), stage IIB in 11 (18%), stage IIIA in 9 (14%), and
stage IIIB in 3 patients (5%). The mean MIB-1 index for
all patients was 62.7% (range, 5.2%–90.5%), and the
mean mitotic count was 71.2/10 HPF (range, 14–153/10
HPF). All 63 patients had tumor necrosis.
Perioperative platinum-based chemotherapy was admin-
istered to 23 (37%) of the 63 patients. We have used the cri-
terion of tumor size more than 3 cm in offering
chemotherapy for patients with stage I disease since 2004.
Thus, 8 of 35 patients with stage I received chemotherapy.
Also, 9 of 16 with stage II and 6 of 12 with stage III received
chemotherapy. Induction chemotherapy was administered
to 3 patients at clinical stage III and adjuvant chemotherapy
was administered to 20 patients at clinical stage I/II. Three
patients received preoperative mediastinal radiotherapy (40
Gy) combined with induction chemotherapy. No patientery c March 2013
TABLE 1. Patient characteristics (n ¼ 63)
Factor Total
Triple
positive
Non–triple
positive P value
Patients (n) 63 31 32
Age (y) .0473
Mean 67.0 64.4 69.5
Range 30–84 30–78 41–84
Gender .2578
Male 54 (87) 25 (81) 29 (91)
Female 9 (13) 6 (19) 3 (9)
Smoking status .1512
Former or current 58 (92) 27 (87) 31 (97)
Never smoked 5 (8) 4 (13) 1 (3)
Surgical procedure .3416
Lobectomy 55 (87) 26 (84) 29 (90)
Segmentectomy 2 (3) 3 (10) 0 (0)
Wedge resection 6 (10) 2 (6) 3 (10)
Pathologic stage .6044
IA 19 (30) 11 (35) 8 (25)
IB 16 (25) 7 (23) 9 (28)
IIA 5 (8) 3 (10) 2 (6)
IIB 11 (18) 3 (10) 8 (25)
IIIA 9 (14) 5 (16) 4 (13)
IIIB 3 (5) 2 (6) 1 (3)
MIB-1 index (%) .5029
Mean 62.7 61.2 64.4
Range 5.2–90.5 5.2–90.0 5.8–90.5
Mitotic counts (/10 HPF) .3538
Mean 71.2 64.7 77.9
Range 14–153 14–122 20–153
Data in parentheses are percentages. Triple positive, Positive for synaptophysin, chro-
mogranin A, and neural cell adhesion molecule; Non–triple positive, negative for 1 or
2 neuroendocrine markers (synaptophysin, chromogranin A, and neural cell adhesion
molecule); HPF, High-powered fields.
TABLE 2. Regimens of perioperative platinum-based chemotherapy
(n ¼ 23)
Regimen
Triple
positive (n ¼ 12)
Non–triple
positive (n ¼ 11)
Induction chemotherapy
CDDPþVP-16 1 0
CDDPþVNR 0 1
CBDCAþDOC 1 0
Adjuvant chemotherapy
CDDPþCPT-11 5 2
CBDCAþPTX 2 4
CDDPþVNR 2 3
CBDCAþVP-16 1 1
Triple positive, Positive for synaptophysin, chromogranin A, and neural cell adhesion
molecule; Non–triple positive, negative for 1 or 2 neuroendocrine markers (synapto-
physin, chromogranin A, and neural cell adhesion molecule); CDDP, cisplatin;
VP-16, etoposide; VNR, vinorelbine; CBDCA, carboplatin; DOC, docetaxel;
CPT-11, irinotecan; PTX, paclitaxel.
TABLE 3. Immunohistochemical staining of 3 neuroendocrine
markers (n ¼ 63)
Neuroendocrine marker Patients (n)
Synaptophysin
Positive 40 (63)
Negative 23 (37)
Chromogranin A
Positive 36 (57)
Negative 27 (43)
NCAM
Positive 59 (94)
Negative 4 (6)
Triple positive 31 (49)
Non–triple positive 32 (51)
Data in parentheses are percentages. NCAM, Neural cell adhesion molecule; Triple
positive, Positive for synaptophysin, chromogranin A, and neural cell adhesion mol-
ecule; Non–triple positive, negative for 1 or 2 neuroendocrine markers (synaptophy-
sin, chromogranin A, and neural cell adhesion molecule).
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regimens are listed in Table 2.
The results of immunohistochemical staining for the 3
neuroendocrine markers are summarized in Table 3. Al-
though the percentage of reactive cells ranged very much,
the intensity of immunostaining was not so variegated for
all 3 neuroendocrine markers. Of the 63 tumors, 40
(63%) were positive for synaptophysin, 36 (57%) for chro-
mogranin A, and 59 (94%) for NCAM. Finally, 31 tumors
(49%) were positive for all 3 neuroendocrine markers and
32 (51%) were negative for 1 or 2 markers. The clinicopath-
ologic characteristics and chemotherapy regimens of pa-
tients in the triple-positive group and non–triple-positive
group are listed in Tables 1and 2, respectively. Although
the triple-positive group was significantly younger than
the non–triple-positive group, no significant differences
were seen in the distribution of other characteristics be-
tween the 2 groups. Also, no morphologic differences
were found between the 2 groups in the neuroendocrine
structures such as rosettes and ribbon-like arrangements,
necrosis, mitotic counts, and MIB-1 index.The Journal of Thoracic and CaThe overall 5-year survival rate among the 63 patients
was 44.9%. Significantly longer survival was observed
for the patients who underwent surgery with chemotherapy
than for those who underwent surgery without chemother-
apy (74.4% and 32.3%, respectively; P ¼ .042; Figure 1,
A).
Next, we evaluated whether the effects of perioperative
chemotherapy were seen in patients with different stages.
Although there was a tendency for longer survival for the
patients with stage I disease who underwent surgery and
chemotherapy compared with those who underwent surgery
without chemotherapy, the small number of subjects did not
allow us to obtain a statistically significant difference
(85.7% and 35.2%, respectively; P ¼ .1129; Figure 1, B).
Similarly, no statistically significant difference in survival
between the patients with and without chemotherapy at
stage II/III (68.8% and 25.6%, respectively; P ¼ .1243;
Figure 1, B). Multivariate analysis of survival wasrdiovascular Surgery c Volume 145, Number 3 841
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FIGURE 1. A, Comparison of survival of patients with large cell neuroendocrine carcinoma who underwent surgery with perioperative chemotherapy and
those who underwent surgery alone. B, Comparison of stage-specific survival of patients with large cell neuroendocrine carcinoma who underwent surgery
with perioperative chemotherapy and those who underwent surgery alone (stage I vs stage II/III). C, Comparison of survival of the non–triple-positive group
and triple-positive group. D, Comparison of survival of the non–triple-positive group and triple-positive group among patients who received perioperative
chemotherapy. E, Comparison of survival of non–triple-positive patients who underwent surgery with perioperative chemotherapy and thosewho underwent
surgery without perioperative chemotherapy. F, Comparison of survival of triple-positive patients who underwent surgery with perioperative chemotherapy
and those who underwent surgery without perioperative chemotherapy. Non–triple positive, Negative for 1 or 2 neuroendocrine markers (synaptophysin,
chromogranin A, and neural cell adhesion molecule); Triple positive, positive for synaptophysin, chromogranin A, and neural cell adhesion molecule.
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TABLE 4. Multivariate analysis of prognostic factors and survival
(Cox proportional hazards model)
Variable HR 95% CI P value
Age (<75 vs 75 y) 1.030 0.466–2.279 .9409
Gender (male vs female) 1.091 0.400–2.967 .8659
Pathologic stage (I vs II/III) 0.645 0.286–1.455 .2904
Surgical procedure (lobectomy vs
sublobar resection)
1.048 0.287–3.824 .9431
Treatment (surgery with
chemotherapy vs surgery alone)
0.323 0.112–0.934 .0371
HR, Hazard ratio; CI, confidence interval.
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pathologic stage, surgical procedure, and surgery with or
without chemotherapy; Table 4). Patients who underwent
surgery with chemotherapy had a significantly better prog-
nosis than those who underwent surgery without chemo-
therapy (hazards ratio, 0.323; 95% confidence interval,
0.112–0.934; P ¼ .0371).
Next, we examined whether the clinical outcome of pa-
tients with LCNEC correlated with the immunohistochem-
ical characteristics determined by immunoreactivity for 3
neuroendocrine markers. No significant difference was
found in 5-year survival between the triple-positive and
non–triple-positive patients (34.0% and 55.3%, respec-
tively; P ¼ .1312; Figure 1, C). No statistically significant
difference was found in survival among the single-
positive, double-positive, and triple-positive patients (data
not shown). Among the patients who received perioperative
chemotherapy, a significantly greater 5-year survival rate
was observed in the non–triple-positive group than in the
triple-positive group (100% and 51.9%, respectively;
P ¼ .0216; Figure 1, D). Moreover, in the non–triple-posi-
tive group, a significantly greater survival rate at 5 years was
observed in patients who underwent surgery with adjuvant
chemotherapy than in those who underwent surgery without
chemotherapy (100% and 34.5%, respectively; P ¼ .0081;
Figure 1, E). In contrast, in the triple-positive group, no dif-
ference was found in 5-year survival between the patients
who underwent surgery with adjuvant chemotherapy and
those who underwent surgery without chemotherapy
(51.8% and 28.1%, respectively; P ¼ .7682; Figure 1, F).
We further analyzed the correlation of chemotherapy
benefits and immunoreactivity patterns of neuroendocrine
markers in patients with different stages. The patients
with stage I and stage II/III did not differ in overall survival
in the non–triple-positive group (53.2% and 56.3%, respec-
tively; P ¼ .8910; Figure 2, A). Survival differences were
also not found in the triple-positive group between stage I
and stage II/III (36.8% and 28.2%, respectively;
P ¼ .6460; Figure 2, B).
Because a limited number of patients with stage I disease
received perioperative chemotherapy, we failed to show
a statistically significant survival difference between theThe Journal of Thoracic and Capatients with and without chemotherapy in the non–triple-
positive patients (100% and 40.6%, respectively;
P ¼ .2002; Figure 2, C) and the triple-positive patients
(80% and 25.2%, respectively; P ¼ .2606; Figure 2, D).
However, perioperative chemotherapy resulted in a signifi-
cantly greater 5-year survival rate in the non–triple-positive
group patients with stage II/III than in the triple-positive
group (100% and 17.9%, respectively; P ¼ .0074;
Figure 2, E). No correlation was found between the use of
perioperative chemotherapy and the survival of patients
with stage II/III disease in the triple-positive group. In the
group of patients with triple-positive tumors, the 5-year sur-
vival rate of the patients with chemotherapy and without
chemotherapy was 34.3% and 33.3%, respectively
(P ¼ .6108; Figure 2, F).
DISCUSSION
Neuroendocrine lung tumors comprise a spectrum of ep-
ithelial neoplasms ranging from low-grade carcinoid tumor
to SCLC. Although most SCLCs show neuroendocrine dif-
ferentiation on immunohistochemistry or electron micros-
copy,13 a significant minority of NSCLCs (approximately
10%–30%) show neuroendocrine differentiation. NSCLCs
with neuroendocrine differentiation are considered to result
in an especially poor prognosis. Several reports have indi-
cated that NSCLCs with neuroendocrine differentiation
were clinically aggressive with greater chemosensitivity;
however, other studies have not shown any correlation.8,14
A 5-year survival rate of 15% to 57% has been reported
for all stages of LCNEC.10,11 Sarkaria and colleagues11 re-
ported a 5-year survival rate of 37% for patients with stage
IB-IIIA LCNEC who did not receive perioperative
platinum-based chemotherapy compared with 51% in those
patients who received it. Saji and colleagues10 reported that
the 5-year survival rate for patients undergoing periopera-
tive chemotherapy was 87.5% and that of patients without
perioperative chemotherapy was 58.5%.10 Our results were
similar.
Thus, we assumed that pulmonary LCNEC might have
several features that make it sensitive to chemotherapy
and tried to evaluate the association between the 3 neuroen-
docrine markers that are essential for the diagnosis of
LCNEC and the responsiveness to chemotherapy. Positive
immunostaining for 1 or more neuroendocrine markers
among synaptophysin, chromogranin A, and NCAM is nec-
essary to diagnose pulmonary LCNEC. Synaptophysin is
a synaptic vesicle glycoprotein with 4 transmembrane do-
mains; however, its exact function is unknown.15 Chromog-
ranin A is the major member of the granin family of acidic
secretory glycoproteins and plays multiple roles in the se-
cretory process.16 NCAM, a glycoprotein, is a member of
the immunoglobulin superfamily and contributes to the
function of cell–cell adhesion.17 Although all 3 markers
are present in neuroendocrine cells, it remains possiblerdiovascular Surgery c Volume 145, Number 3 843
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FIGURE 2. A,Comparison of stage-specific survival of patientswith non–triple-positive large cell neuroendocrine carcinoma. B,Comparison of stage-specific
survival of patients with triple-positive large cell neuroendocrine carcinoma. C, Comparison of survival of patients with stage I nontriple-positive disease who
underwent surgerywith perioperative chemotherapy and thosewhounderwent surgerywithoutperioperative chemotherapy.D,Comparison of survival of patients
with stage I triple-positive who underwent surgery with perioperative chemotherapy and those who underwent surgery without perioperative chemotherapy. E,
Comparison of survival of patientswith stage II/III non–triple-positive diseasewhounderwent surgerywith perioperative chemotherapy and thosewhounderwent
surgery without perioperative chemotherapy. F, Comparison of survival of patients with stage II/III triple-positive disease who underwent surgery with perioper-
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that neuroendocrine markers are often negative in poorly
differentiated neuroendocrine cancers,18 and it is estimated
that LCNEC in the non–triple-positive group tended to be
poorly differentiated and associated with a poor prognosis.
Our results have demonstrated that the 5-year survival rate
of patients who did not undergo perioperative chemother-
apy in the non–triple-positive group was 34.5%. The addi-
tion of perioperative chemotherapy improved the prognosis
of LCNEC in the non–triple-positive group but did not im-
prove the prognosis of LCNEC in the triple-positive group.
We considered that LCNEC might become resistant to che-
motherapy through coexistence and mutual interaction of
synaptophysin, chromogranin A, and NCAM and might
lose the ability to resist because of the deficiency of the mu-
tual interaction, owing to a lack of any of the 3 proteins.
Various studies have analyzed LCNEC’s prognostic fac-
tors using other immunohistochemical staining and gene ex-
pression profiles.19-21 However, no report has more clearly
demonstrated the sensitivity of pulmonary LCNEC to
perioperative chemotherapy than has our study. Moreover,
it is also considered valuable that we can describe this
result with 3 well-known biomarkers that are necessary for
the diagnosis of pulmonary LCNEC. Furthermore, it was re-
ported that carcinoids that exhibit good prognosis have a low
response rate to chemotherapy and SCLCs that show a poor
prognosis have a high initial response rate to chemother-
apy.18,22 Considered with our results, it is likely that triple-
positive LCNEC was rich in neuroendocrine character,
similar to carcinoids, and the non–triple-positive LCNECs
were poor in neuroendocrine character, similar to SCLCs.
In the present study, antibody staining was designated as
negative when none of the tumor cells were stained and as
positive when any degree of immunoreactivity was found.
We determined the cutoff value using the following scoring
system: 0, no positive cells; 1þ, less than 10% of cells pos-
itive; 2þ, 10% to 50% of cells positive; and 3þ, more than
50% of cells positive. From this analysis, the optimal
cutoff, defined as the value that best separated a poor prog-
nostic group from a better prognostic group, was nonimmu-
noreactive (negative) vs immunoreactive (positive) for the
neuroendocrine markers. The evaluation separating ‘‘posi-
tive’’ from ‘‘negative,’’ without any counting of cells, was
easily and quickly performed with high reproducibility,
which could be an advantage in possible future use in the
clinical setting.
At present, most LCNECs are diagnosed using surgically
resected specimens and rarely using biopsy or cytology
specimens. Almost all publications concerning resected
LCNEC have been based on the retrospective analyses of
surgical specimens.23 We used postoperative specimens to
diagnose pulmonary LCNEC and to categorize them as ei-
ther triple positive or non–triple positive. However, it would
be difficult to categorize LCNEC according to our criteriaThe Journal of Thoracic and Causing small biopsy specimens or cytologic specimens be-
cause heterogeneity and focal and scattered positivity of im-
munostaining against the neuroendocrine markers are not
unusual. Therefore, this method might not be applicable
for neoadjuvant chemotherapy.
Regarding the perioperative chemotherapy regimens for
pulmonary LCNEC, platinum-based regimens that include
etoposide (VP-16) or irinotecan (CPT-11), which are stan-
dard for SCLC, are more effective than other platinum-
based regimens for NSCLCs, because pulmonary LCNEC
is genetically and immunohistochemically more similar to
SCLC than to NSCLC.10,24,25 In our study, 10 (43%) of
the 23 patients underwent a platinum-based regimen that
included VP-16 or CPT-11. In addition, 3 (27%) of 11 pa-
tients in the non–triple-positive group received a platinum-
based regimen that included VP-16 or CPT-11, in contrast
to 7 (58%) of 12 patients in the triple-positive group. We
considered that our result (ie, the sensitivity of LCNEC to
perioperative chemotherapy in the non–triple-positive
group), was not affected by the regimen of chemotherapy
that included VP-16 or CPT-11.
Evidence is increasing that surgical resection alone is insuf-
ficient as treatment of LCNEC, even for stage I disease, and
perioperative platinum-based chemotherapy might provide
a survival advantage for patients with stage I LCNEC.9,10
Our results have demonstrated that patients with stage I
LCNEC tended to benefit from perioperative chemotherapy,
although we failed to demonstrate a significant difference
because only a small number of patients with stage I
received perioperative chemotherapy. In the patients with
stage I, perioperative chemotherapy tended to be associated
with longer survival in the non–triple-positive group, as
well as in the triple-positive group.
Although we acknowledge our study’s limitations (a
small number of subjects and short-term follow-up), our re-
sults have demonstrated that perioperative chemotherapy
can enhance survival for the patients in the non–triple-pos-
itive group, although no correlation was seen between che-
motherapy and survival in the triple-positive group. We
believe these preliminary results are a reasonable rationale
for a larger study to determine the correlation between che-
motherapy response and neuroendocrine immunoreactivity
in patients with LCNEC.
CONCLUSIONS
Our results have suggested that perioperative chemo-
therapy can be an important therapeutic option in the
treatment of pulmonary LCNEC, particularly in the
non–triple-positive patients. In the future, prospective
multi-institutional studies with larger sample sizes should
be conducted to verify the validity of our findings. Contin-
ued studies, including molecular studies, are also impor-
tant to further improve the treatment stratification of
patients with LCNEC.rdiovascular Surgery c Volume 145, Number 3 845
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